share_log

Portage Biotech Says Is Well Funded To Leverage Its Product Engine To Deliver On Clinical Milestones Through End Of 2023

Portage Biotech Says Is Well Funded To Leverage Its Product Engine To Deliver On Clinical Milestones Through End Of 2023

Porage Biotech表示，該公司資金充足，可以利用其產品引擎在2023年底之前實現臨牀里程碑
Benzinga Real-time News ·  2022/03/31 20:06

Portage Biotech Says Is Well Funded To Leverage Its Product Engine To Deliver On Clinical Milestones Through End Of 2023

Porage Biotech表示，該公司資金充足，可以利用其產品引擎在2023年底之前實現臨牀里程碑

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論